Laboratory of Molecular Biology and Functional Genomics, Centro de Investigación en Alimentación y Desarrollo, Culiacán, Sinaloa, A.C. (CIAD), Mexico.
CONACYT-Centro de Investigación en Alimentación y Desarrollo A.C. (CIAD), Culiacán, Sinaloa, Mexico.
Folia Microbiol (Praha). 2023 Feb;68(1):1-16. doi: 10.1007/s12223-022-00990-5. Epub 2022 Aug 5.
Pseudomonas aeruginosa (PA) is considered the first causal agent of morbidity and mortality in people with cystic fibrosis (CF) disease. Multi-resistant strains have emerged due to prolonged treatment with specific antibiotics, so new alternatives have been sought for their control. In this context, there is a renewed interest in therapies based on bacteriophages (phages) supported by several studies suggesting that therapy based on lytic phages and biofilm degraders may be promising for the treatment of lung infections in CF patients. However, there is little clinical data about phage studies in CF and the effectiveness and safety in patients with this disease has not been clear. Therefore, studies regarding on phage characterization, selection, and evaluation in vitro and in vivo models will provide reliable information for designing effective cocktails, either using mixed phages or in combination with antibiotics, making a great progress in clinical research. Hence, this review focuses on the most relevant and recent findings on the activity of lytic phages against PA strains isolated from CF patients and hospital environments, and discusses perspectives on the use of phage therapy on the treatment of PA in CF patients.
铜绿假单胞菌（PA）被认为是囊性纤维化（CF）疾病患者发病和死亡的首要原因。由于长期使用特定抗生素治疗，已经出现了多耐药菌株，因此人们一直在寻找新的替代品来控制它们。在这种情况下，人们重新关注基于噬菌体（噬菌体）的疗法，这得到了多项研究的支持，这些研究表明，基于裂解噬菌体和生物膜降解剂的治疗方法可能对 CF 患者肺部感染的治疗有希望。然而，关于 CF 中噬菌体研究的临床数据很少，并且这种疾病患者的有效性和安全性尚不清楚。因此，关于噬菌体在体外和体内模型中的特征描述、选择和评估的研究将为设计有效的鸡尾酒疗法提供可靠信息，无论是使用混合噬菌体还是与抗生素联合使用，这都将在临床研究中取得重大进展。因此，本综述重点介绍了针对从 CF 患者和医院环境中分离出的 PA 菌株的裂解噬菌体的最相关和最新研究结果，并讨论了噬菌体治疗在 CF 患者 PA 治疗中的应用前景。
